852
Participants
Start Date
September 30, 2010
Primary Completion Date
February 28, 2014
Study Completion Date
March 31, 2020
Alemtuzumab
Alemtuzumab 30 mg intravenously or subcutaneously, two doses 24 hours apart
Basiliximab
20 mg intravenously, two doses 96 hours apart
Sirolimus
Sirolimus: target trough levels 6-12 ng/mL for first 6-months after maintenance therapy randomization, then 5-10 ng/mL
Tacrolimus
Tacrolimus: target trough levels 5-7 ng/mL after maintenance therapy randomization.
Oxford Radcliffe Hospitals NHS Trust, Oxford
University Hospitals Birmingham NHS Foundation Trust, Birmingham
Addenbrooke's Hospital NHS Trust, Cambridge
University Hospital of Wales, Cardiff
University Hospitals Coventry & Warwickshire, Coventry
Royal Infirmary, Edinburgh
Western Infirmary, Glasgow
Hull and East Yorkshire Hospitals NHS Trust, Hull
Leeds Teaching Hospitals NHS Trust, Leeds
Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool
Bart's and the London NHS Trust, London
Guy's and St Thomas's NHS Trust, London
Kings College Hospital NHS Trust, London
Royal Free Hampstead NHS Trust, London
Central Manchester NHS Trust, Manchester
Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle
Nottingham University Hospitals NHS Trust, Nottingham
Plymouth Teaching Hospitals NHS Trust, Plymouth
Portsmouth Hospitals NHS Trust, Portsmouth
Sheffield Teaching Hospitals NHS Trust, Sheffield